Translational Development Acquisition TDAC
NASDAQ TDAC
$10.85 +0.01 (+0.05%)
As of: Aug 21, 2026 · 3:58 PM EDT

Translational Development Acquisition (TDAC) Return on Capital Employed (2025 - 2026)

Translational Development Acquisition's (TDAC) quarterly Return on Capital Employed came in at 0.48% in Q1 2026, up 7.71% on a QoQ basis from 0.52% in Q4 2025.

Translational Development Acquisition (TDAC) Return on Capital Employed (2025 - 2026) Analysis & Trends

Translational Development Acquisition (TDAC) has 2 years of Return on Capital Employed data on file, last reported at 0.48% in Q1 2026.

  • Quarterly Return on Capital Employed changed N/A year-over-year to 0.48% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.48% (changed N/A YoY) and the FY2025 annual result came in at 0.53%, down 31.0% from the prior year.
  • Return on Capital Employed climbed to 0.48% in Q1 2026, from 0.52% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.43% in Q2 2025 to a low of 0.52% in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROCE (Qtr)
1 Oxley Bridge Acquisition 585.76 Mn 585.76 Mn - -0.24%
2 Launch Two Acquisition 557.86 Mn 557.86 Mn - -0.37%
3 Drugs Made In America Acquisition 507.00 Mn 507.00 Mn - -
4 Cantor Equity Partners IV 468.00 Mn 468.00 Mn - -
5 GP-Act III Acquisition 401.06 Mn 401.06 Mn - -0.90%
6 Aldel Financial 397.49 Mn 397.49 Mn - -0.29%
7 Republic Digital Acquisition 389.25 Mn 388.51 Mn - -0.14%
8 Gores Holdings X 385.06 Mn 384.87 Mn - -0.86%
9 Agriculture & Natural Solutions Acquisition 377.29 Mn 377.04 Mn - -
10 Translational Development Acquisition 182.66 Mn 182.57 Mn - -0.78%

Historic Data

Download Data
DateValue
Mar 31, 2026 -0.48%
Dec 31, 2025 -0.52%
Sep 30, 2025 -0.51%
Jun 30, 2025 -0.43%